Prof Jens Kuhle, MD, PhD, from the University of Basel in Switzerland, highlights key studies in relapsing-remitting multiple sclerosis (RRMS), presented at the 2022 annual meeting of the European Academy of Neurology (EAN).
First, Prof Kuhle discusses updates to the EAN– European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) guidelines for MS treatment. Specifically, he notes recommendations for disease-modifying therapy in patients with MS who are pregnant or wish to become pregnant.
He then reports on a study indicating spinal cord damage as an important prognostic biomarker for disease worsening.
Next, Prof Kuhle surveys recent headway in the development of prognostic biomarkers in MS. He reports on the growing reliability of serum neurofilament light chain (sNfL) levels as well as emerging biomarkers that may prove to be highly sensitive in predicting disease progression.
Prof Kuhle closes by highlighting a study focused on the Bruton's tyrosine kinase (BTK) inhibitor evobrutinib in patients with RRMS. Findings showed that higher doses reduced MRI activity as well as relapses when stratifying for baseline sNfL levels.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Jens Kuhle. Relapsing-Remitting Multiple Sclerosis Highlights From EAN 2022 - Medscape - Jul 27, 2022.
Comments